Literature DB >> 33333804

Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis.

Ali Yousefian-Jazi1, YunHee Seol1, Jieun Kim1, Hannah L Ryu2, Junghee Lee2,3, Hoon Ryu1,2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is the most frequent motor neuron disease and a neurodegenerative disorder, affecting the upper and/or lower motor neurons. Notably, it invariably leads to death within a few years of onset. Although most ALS cases are sporadic, familial amyotrophic lateral sclerosis (fALS) forms 10% of the cases. In 1993, the first causative gene (SOD1) of fALS was identified. With rapid advances in genetics, over fifty potentially causative or disease-modifying genes have been found in ALS so far. Accordingly, routine diagnostic tests should encompass the oldest and most frequently mutated ALS genes as well as several new important genetic variants in ALS. Herein, we discuss current literatures on the four newly identified ALS-associated genes (CYLD, S1R, GLT8D1, and KIF5A) and the previously well-known ALS genes including SOD1, TARDBP, FUS, and C9orf72. Moreover, we review the pathogenic implications and disease mechanisms of these genes. Elucidation of the cellular and molecular functions of the mutated genes will bring substantial insights for the development of therapeutic approaches to treat ALS.

Entities:  

Keywords:  amyotrophic lateral sclerosis; cell damage; genome signature; motor neuron; neurodegeneration

Year:  2020        PMID: 33333804      PMCID: PMC7765192          DOI: 10.3390/cells9122687

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  177 in total

1.  A yeast functional screen predicts new candidate ALS disease genes.

Authors:  Julien Couthouis; Michael P Hart; James Shorter; Mariely DeJesus-Hernandez; Renske Erion; Rachel Oristano; Annie X Liu; Daniel Ramos; Niti Jethava; Divya Hosangadi; James Epstein; Ashley Chiang; Zamia Diaz; Tadashi Nakaya; Fadia Ibrahim; Hyung-Jun Kim; Jennifer A Solski; Kelly L Williams; Jelena Mojsilovic-Petrovic; Caroline Ingre; Kevin Boylan; Neill R Graff-Radford; Dennis W Dickson; Dana Clay-Falcone; Lauren Elman; Leo McCluskey; Robert Greene; Robert G Kalb; Virginia M-Y Lee; John Q Trojanowski; Albert Ludolph; Wim Robberecht; Peter M Andersen; Garth A Nicholson; Ian P Blair; Oliver D King; Nancy M Bonini; Vivianna Van Deerlin; Rosa Rademakers; Zissimos Mourelatos; Aaron D Gitler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis.

Authors:  Matthew J Greenway; Peter M Andersen; Carsten Russ; Sean Ennis; Susan Cashman; Colette Donaghy; Victor Patterson; Robert Swingler; Dairin Kieran; Jochen Prehn; Karen E Morrison; Andrew Green; K Ravi Acharya; Robert H Brown; Orla Hardiman
Journal:  Nat Genet       Date:  2006-02-26       Impact factor: 38.330

3.  Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia.

Authors:  P M Andersen; P Nilsson; M L Keränen; L Forsgren; J Hägglund; M Karlsborg; L O Ronnevi; O Gredal; S L Marklund
Journal:  Brain       Date:  1997-10       Impact factor: 13.501

Review 4.  Management and therapeutic perspectives in amyotrophic lateral sclerosis.

Authors:  Stéphane Mathis; Philippe Couratier; Adrien Julian; Jean-Michel Vallat; Philippe Corcia; Gwendal Le Masson
Journal:  Expert Rev Neurother       Date:  2016-09-20       Impact factor: 4.618

5.  Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration.

Authors:  Nathalie Bernard-Marissal; Jean-Jacques Médard; Hamid Azzedine; Roman Chrast
Journal:  Brain       Date:  2015-02-11       Impact factor: 13.501

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

7.  Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia.

Authors:  Han-Xiang Deng; Wenjie Chen; Seong-Tshool Hong; Kym M Boycott; George H Gorrie; Nailah Siddique; Yi Yang; Faisal Fecto; Yong Shi; Hong Zhai; Hujun Jiang; Makito Hirano; Evadnie Rampersaud; Gerard H Jansen; Sandra Donkervoort; Eileen H Bigio; Benjamin R Brooks; Kaouther Ajroud; Robert L Sufit; Jonathan L Haines; Enrico Mugnaini; Margaret A Pericak-Vance; Teepu Siddique
Journal:  Nature       Date:  2011-08-21       Impact factor: 49.962

Review 8.  ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

Authors:  Dmitry Petrov; Colin Mansfield; Alain Moussy; Olivier Hermine
Journal:  Front Aging Neurosci       Date:  2017-03-22       Impact factor: 5.750

9.  Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.

Authors:  Ze'ev Melamed; Jone López-Erauskin; Michael W Baughn; Ouyang Zhang; Kevin Drenner; Ying Sun; Fernande Freyermuth; Moira A McMahon; Melinda S Beccari; Jon W Artates; Takuya Ohkubo; Maria Rodriguez; Nianwei Lin; Dongmei Wu; C Frank Bennett; Frank Rigo; Sandrine Da Cruz; John Ravits; Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Nat Neurosci       Date:  2019-01-14       Impact factor: 24.884

10.  Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.

Authors:  Mercedes Prudencio; Jack Humphrey; Sarah Pickles; Anna-Leigh Brown; Sarah E Hill; Jennifer M Kachergus; J Shi; Michael G Heckman; Matthew R Spiegel; Casey Cook; Yuping Song; Mei Yue; Lillian M Daughrity; Yari Carlomagno; Karen Jansen-West; Cristhoper Fernandez de Castro; Michael DeTure; Shunsuke Koga; Ying-Chih Wang; Prasanth Sivakumar; Cristian Bodo; Ana Candalija; Kevin Talbot; Bhuvaneish T Selvaraj; Karen Burr; Siddharthan Chandran; Jia Newcombe; Tammaryn Lashley; Isabel Hubbard; Demetra Catalano; Duyang Kim; Nadia Propp; Samantha Fennessey; Delphine Fagegaltier; Hemali Phatnani; Maria Secrier; Elizabeth Mc Fisher; Björn Oskarsson; Marka van Blitterswijk; Rosa Rademakers; Neil R Graff-Radford; Bradley F Boeve; David S Knopman; Ronald C Petersen; Keith A Josephs; E Aubrey Thompson; Towfique Raj; Michael Ward; Dennis W Dickson; Tania F Gendron; Pietro Fratta; Leonard Petrucelli
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 19.456

View more
  6 in total

1.  Deviation from baseline mutation burden provides powerful and robust rare-variants association test for complex diseases.

Authors:  Lin Jiang; Hui Jiang; Sheng Dai; Ying Chen; Youqiang Song; Clara Sze-Man Tang; Shirley Yin-Yu Pang; Shu-Leong Ho; Binbin Wang; Maria-Mercedes Garcia-Barcelo; Paul Kwong-Hang Tam; Stacey S Cherny; Mulin Jun Li; Pak Chung Sham; Miaoxin Li
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

Review 2.  Role of SNAREs in Neurodegenerative Diseases.

Authors:  Azzurra Margiotta
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

Review 3.  Moving Toward Patient-Tailored Treatment in ALS and FTD: The Potential of Genomic Assessment as a Tool for Biological Discovery and Trial Recruitment.

Authors:  Iris J Broce; Patricia A Castruita; Jennifer S Yokoyama
Journal:  Front Neurosci       Date:  2021-03-01       Impact factor: 4.677

4.  A Deletion of the Nuclear Localization Signal Domain in the Fus Protein Induces Stable Post-stress Cytoplasmic Inclusions in SH-SY5Y Cells.

Authors:  Antonietta Notaro; Antonella Messina; Vincenzo La Bella
Journal:  Front Neurosci       Date:  2021-12-23       Impact factor: 4.677

5.  Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients.

Authors:  Assunta Ingannato; Silvia Bagnoli; Salvatore Mazzeo; Valentina Bessi; Sabrina Matà; Monica Del Mastio; Gemma Lombardi; Camilla Ferrari; Sandro Sorbi; Benedetta Nacmias
Journal:  Front Neurosci       Date:  2021-09-03       Impact factor: 4.677

6.  A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.

Authors:  Gaël Nicolas; Myriam Sévigny; François Lecoquierre; Florent Marguet; Andréanne Deschênes; Maria Carment Del Pelaez; Sébastien Feuillette; Anaïs Audebrand; Magalie Lecourtois; Stéphane Rousseau; Anne-Claire Richard; Kévin Cassinari; Vincent Deramecourt; Charles Duyckaerts; Anne Boland; Jean-François Deleuze; Vincent Meyer; Jordi Clarimon Echavarria; Ellen Gelpi; Haruhiko Akiyama; Masato Hasegawa; Ito Kawakami; Tsz H Wong; Jeroen G J Van Rooij; John C Van Swieten; Dominique Campion; Paul A Dutchak; David Wallon; Flavie Lavoie-Cardinal; Annie Laquerrière; Anne Rovelet-Lecrux; Chantelle F Sephton
Journal:  Acta Neuropathol Commun       Date:  2022-02-12       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.